M. Agelidou

A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancer

Dimitriοs Mavroudis, E. Papadakis, M. Veslemes et al. · Annals of Oncology · 2001 · 159 citations · Full text

Paclitaxel–cisplatin–etoposide Versus Cisplatin–etoposide, Medicine, Metronomic Therapy +10

Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial

Vassilis Georgoulias, Alexandros Ardavanis, Athina Agelidou et al. · Journal of Clinical Oncology · 2004 · 134 citations · Full text

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Athanasios Karampeazis, Alexandra Voutsina, John Souglakos et al. · Cancer · 2013 · 111 citations · Full text

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

Vassilis Georgoulias, N. Androulakis, Meletios Α. Dimopoulos et al. · Annals of Oncology · 1998 · 71 citations

Medicine, Metronomic Therapy, Bronchial Neoplasm +8

Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel–gemcitabine chemotherapy

Athanasios Pallis, Sofia Agelaki, S. Kakolyris et al. · Lung Cancer · 2008 · 46 citations

Medicine, Front-line Docetaxel–gemcitabine Chemotherapy, Prognostic Factor +9